Apply to trial NCT07223229

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Biological intervention

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening